

Contents

Section 1: Basics of Biologics

- 1. History and Development of Biologics** **3**
Biju Vasudevan, Ankan Gupta
- 2. Classification of Biologics** **9**
Aradhana Rout
- 3. Concept and Development of Biosimilars** **17**
Brijesh Nair

Section 2: Biologics in Psoriasis

- 4. Pathogenesis of Psoriasis** **33**
Rajat Kandhari, Snigdha Saxena, Anupama Molpariya
- 5. Etanercept** **51**
Santanu Banerjee, Debatraya Paul
- 6. Infliximab** **65**
Biju Vasudevan, Shekhar Neema
- 7. Adalimumab** **75**
Vinay Singh
- 8. IL-17 Blockers: Secukinumab** **84**
SG Parasramani, D Joshika Bhandary
- 9. Ixekizumab** **96**
Aseem Sharma, Ravina Surve
- 10. Anti-CD6 Monoclonal Antibody: Itolizumab** **106**
Krupashankar DS, Swaroop HS
- 11. Interleukin-36 Receptor Antagonist: Spesolimab** **114**
Ruchi Hemdani
- 12. Newer Biologics in Psoriasis** **122**
Siddharth Mani, Abir Saraswat

Section 3: Biologics in Immunobullous Disorders

- 13. Biologics in the Management of Pemphigus—Anti-CD20 Monoclonal Antibody: Rituximab** **145**
Dipankar De, Hitaishi Mehta, Muhammed Razmi T
- 14. Newer Biologics in the Management of Immunobullous Disorders** **167**
Surbhi Rajput

Section 4: Biologics in Urticaria

- 15. Anti-IgE Monoclonal Antibody: Omalizumab** **179**
Kiran Godse, Bhojani Amee
- 16. Newer Biologics in Urticaria** **186**
Shreya Poddar, Indrashish Podder

Section 5: Biologics in Atopic Dermatitis

- 17. Interleukin-4 Inhibitor: Dupilumab** **199**
Sandipan Dhar, Disha Chakraborty, Abhishek De
- 18. Newer Biologics in the Management of Atopic Dermatitis** **212**
Disha Chakraborty, Abhishek De

Section 6: Biologic Approach to Management of Various Diseases

- 19. Psoriasis** **231**
Murlidhar Rajagopalan, Shekhar Neema, Ankan Gupta, Manish Khandare, Manas Chatterjee
- 20. Immunobullous Disorders** **252**
Himadri, Ankan Gupta
- 21. Hidradenitis Suppurativa** **262**
Sharmila Patil, Aarti Zope
- 22. Use of Biologics in Dermatological Aspects of Autoimmune Rheumatic Diseases** **275**
Shivraj Padiyar, Prathyusha Manikuppam

Section 7: Biologics and Chronic Infections

- 23. Management of Latent Tuberculosis Infection** **287**
Bhushan Madke, Swetalina Pradhan
- 24. Biologics in Presence of Hepatitis B and C Infection** **300**
Shekhar Neema, Manish Manrai

Section 8: Biologics in Special Situation

- 25. Biologics in Children: Which, When, Why?** **313**
Khushboo Minni, Resham Vasani
- 26. Biologics in Pregnancy, Lactation, and Other Situations** **341**
Shekhar Neema, Vikas Pathania

Section 9: Miscellaneous Issues with Biologics

- 27. Miscellaneous Uses of Biologics** **357**
Manas Chatterjee, Dipali Rathod
- 28. Adverse Effects of Biologics: Feared or Real?** **369**
Sunil Dogra, Narayanan B
- 29. Adult Immunization Prior to Initiation of Biologic Therapy** **397**
Ankan Gupta, Himadri
- 30. Cost Effectiveness and Quality of Life with Biologic Therapy** **409**
Ankan Gupta, Jaya Krishna, Shekhar Neema

Section 10: Small Molecules and IVIG

- 31. Janus Kinase Inhibitors** **437**
Part A: Classification of Janus Kinase Inhibitors **437**
Siddharth Mani, Manish Khandare
Part B: Tofacitinib **442**
Siddharth Mani, Manish Khandare
Part C: Other JAK Inhibitors: Baricitinib, Abrocitinib, and Upadacitinib **454**
Ruchi Hemdani
Part D: Newer Janus Kinase Inhibitors **467**
Padmapriya Srinivasan
- 32. Phosphodiesterase-4 Inhibitors** **482**
Anupam Das, Kingshuk Chatterjee
- 33. Mammalian Target of Rapamycin Inhibitors: Sirolimus** **489**
Riti Bhatia, Vishal Gupta
- 34. Newer Small Molecules in Pipeline** **501**
Bhavni Oberoi
- 35. Intravenous Immunoglobulins** **512**
Rohit Kothari, Rajesh Verma
- 36. Ready Reckoner for Biologics and Small Molecules** **525**
Bhavni Oberoi, Shekhar Neema

- Index** **531**